New Standard Notification – ISO 4768:2023 the measurement of anti-biofilm activity on plastic and other non-porous surfaces was released this month.
This marks a key progressive step in anti-biofilm testing standards. The method is to support material development and...
New and novel products are a necessity in the medical device market. Industry investment in innovation delivers life enhancing healthcare devices, diagnostics, and digital solutions. Hand-in-hand with product innovation is its innovative test methods, to support efficacy...
We are once again supporting the NBIC Biofilm Week 2022 campaign, highlighting research to prevent, detect, manage, and engineer biofilms.
Perfectus Biomed Group, now part of NAMSA, are thrilled to take this opportunity to launch our Biofilm Spotlight Interview Series....
In order to ensure medical devices are safe for use, regulatory bodies require manufacturers to demonstrate adequate inactivation and removal of viruses. Perfectus Biomed, now part of NAMSA, can help you with this key validation step.
A crucial element in the product...
NAMSA, a world-leading MedTech Contract Research Organization (CRO) offering global end-to-end development services, announced today its acquisition of Perfectus Biomed Group, a UK founded laboratory, providing customized microbiological services.
“Perfectus Biomed Group...
What is Monkeypox?
On the 23rd July 2022, the World Health Organisation declared the spread of monkeypox as a public health emergency of international concern. Countries in Europe have recorded high cases, but there have also been reports in the US, Canada, Australia,...
NAMSA, a world-leading MedTech Contract Research Organization (CRO) offering global end-to-end development services, announced today its acquisition of Perfectus Biomed Group, a UK founded laboratory, providing customized microbiological services.
“Perfectus Biomed Group...
